MUMBAI and BALTIMORE — Lupin has introduced its generic of Fosrenol (lanthanum carbonate) chewable tablets. The company’s alliance partner, Natco, had previously received approval for the tablets from the Food and Drug Administration.
The drug is indicated to reduce serum phosphate in patients with end-stage renal disease. Lupin’s generic will be available in 500-, 750- and 100-mg (base) dosage strengths.
The product had an estimated market size of $122.4 million, according to QuintilesIMS data for the 12 months ended June 2017.